NAIROBI, Kenya — Group CEO of Amref Health Africa Dr. Githinji Gitahi has lauded the Kenyan government and the Global Fund for introducing Lenacapavir, a twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention, but emphasized that equity must guide distribution.
Dr. Gitahi highlighted that the initial supply of Lenacapavir is limited and urged authorities to prioritize access for those most at risk of HIV infection.
“I urge the government to ensure equity so these few doses go to those most deserving and most at risk,” he said.
Lenacapavir, administered twice a year, is designed to prevent HIV in individuals who are HIV-negative but at high risk.
I laud the Government of Kenya through the @MOH_Kenya and the @GlobalFund for their visionary leadership in enabling access to life-saving innovation.I URGE the government to ensure EQUITY so these FEW doses go to those most deserving and most at risk!The arrival of
Experts have emphasized that it is not a vaccine and does not replace long-term HIV treatment for those living with the virus.
Dr. Gitahi reminded the public that Lenacapavir should be used alongside existing HIV prevention measures, including consistent condom use, safe sex practices, and regular testing.
“Lenacapavir is not a replacement for long-term HIV treatment for those living with HIV, nor is it a vaccine – it’s a pre-exposure injection for those negative but are at high risk of infection,” he said.
The Ministry of Health has indicated that the rollout will initially focus on targeted populations, with guidance and follow-up from healthcare providers.
Dr. Gitahi’s comments underline the importance of fair access, particularly as Kenya moves toward achieving its HIV prevention goals and global health targets.
“Together, we can build a healthier, HIV-free future for all Kenyans,” Dr Gitahi said.
Kenya this week received its first 21,000 starter doses of Lenacapavir, a long‑acting injectable HIV pre‑exposure prophylaxis (PrEP) designed to prevent HIV infection with just two injections a year.
It will be introduced in a phased rollout starting in March 2026, with initial distribution planned across 15 high‑burden counties including Nairobi, Mombasa, Kisumu, Nakuru, Kilifi and others.
The Ministry of Health will implement the programme through public hospitals and county health facilities under the National AIDS and STI Control Programme.